

# DILI-sim Consortium

Join the DILI-sim Consortium to have a front row seat as we launch a new chapter in the scientific development of the DILIsym® model. In the next three years (2027-2030), we will make major advancements to address emerging areas of liver safety concerns.



## Proposed Advances in DILIsym

- Development of AI-powered DILIsym agents to improve workflow efficiency, including
  - Speeding translation of *in vitro* data to DILIsym input parameters
  - Facilitating use of Liver Safety+ to predict safety for early discovery / lead optimization compounds
- Expanded cholestatic and mixed DILI representation to address alternate mechanisms and forms of clinical DILI presentation
- New specific simulated populations (SimPops®) to address populations of special interest
- Release of BIOLOGXsym v1.0 for the prediction of large molecule liver safety
  - Expansion of large molecule library, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs)
- Addition of liver injury due to gene therapies (e.g. siRNA, adeno-associated virus)
- Accommodating liver-on-a-chip inputs

Member input determines the direction of future DILIsym development, ensuring that DILIsym grows to meet your organization's needs. In addition to the points above, the DILIsym team proposes expanding the representation of pediatric DILI and expanding the DILIsym compound library to include more cholestatic and T cell implicated DILI compounds. The team welcomes additional ideas from Member companies.

 **Learn More:** [Lisl.Shoda@simulations-plus.com](mailto:Lisl.Shoda@simulations-plus.com)

## Benefits of Membership

Consortium benefits will extend beyond DILIsym applications.

- Voting rights to prioritize scientific development of the DILIsym model
- Quarterly updates on DILIsym development, including insights from (blinded) DILIsym proprietary projects
- Two user seats for newly released versions of the DILIsym model, as well as to RENAsym® v3A
- 10 hours of DILIsym training annually per Member company
- Early access to DILIsym AI agentic workflows
- Trial access to S+ AI tools in other platforms
- Annual innovation credit which can be applied to any Services work in any S+ platform
- Membership discounts for Members that share data for testing and publication

## Why DILIsym?

- 67** Biopharmaceutical sponsors that have engaged S+ to execute a DILIsym project
- 50** FDA communications that have included DILIsym results
- 8** Approved drugs that have benefited from DILIsym results
- “**“DILIsym can be considered the current state-of-the-art for predicting DILI” ([Goldring et al. 2025](#))
- “**“DILIsym is the “most widely used QST modeling software for DILI prediction” and the modeling results have sometimes been requested by the FDA ([Chalasani et al. 2025](#))

Rev. 8/4/26